                         SEQUENCE LISTING

<110>  Recombinetics, Inc.
 
<120>  PRODUCTION OF FMDV-RESISTANT LIVESTOCK BY ALLELE SUBSTITUTION

<130>  5054.17US02

<140>  13836860
<141>  2013-05-15

<150>  61/677,904
<151>  2012-07-31

<160>  18    

<170>  PatentIn version 3.5

<210>  1
<211>  12
<212>  PRT
<213>  Sus scrofa

<400>  1

Pro Ser Phe Ala Asn Leu Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  2
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform for eIF4G

<400>  2

Pro Ser Phe Ala Asp Phe Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  3
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform of eIF4G

<400>  3

Pro Ser Phe Ala Asn Leu Gly Pro Pro Ala Leu Ser 
1               5                   10          


<210>  4
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform of eIF4G

<400>  4

Pro Ser Phe Ala Asn Phe Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  5
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform for eIF4G

<400>  5

Pro Ser Phe Ala Asn Asp Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  6
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform for eIF4G

<400>  6

Pro Ser Phe Ala Asn Pro Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  7
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform for eIF4G

<400>  7

Pro Ser Phe Ala Asn Tyr Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  8
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform eIF4G

<400>  8

Pro Ser Phe Ala Asn Trp Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  9
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform eIF4G

<400>  9

Pro Ser Phe Ala Asp Leu Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  10
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform eIF4G

<400>  10

Pro Ser Phe Pro Asn Leu Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  11
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  isoform eIF4G

<400>  11

Pro Ser Phe Asp Asn Leu Gly Arg Pro Ala Leu Ser 
1               5                   10          


<210>  12
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  TALEN portion

<400>  12
ccgtcctttg ccaacctt                                                     18


<210>  13
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  TALEN portion

<400>  13
agcaaccgtg ggccccca                                                     18


<210>  14
<211>  16
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  TALEN portion

<400>  14
tggccgacca gccctt                                                       16


<210>  15
<211>  15
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  TALEN portion

<400>  15
cccaaggggt gggcc                                                        15


<210>  16
<211>  73
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  portion of EIF4GI gene

<400>  16
cagacttcac tccgtccttt gccaaccttg gccgaccagc ccttagcaac cgtgggcccc       60

caaggggtgg gcc                                                          73


<210>  17
<211>  73
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  EIF4GI gene portion isoform

<400>  17
cagacttcac tccgtccttt gccgacttcg gccgaccagc ccttagcaac cgtgggcccc       60

caaggggtgg gcc                                                          73


<210>  18
<211>  90
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  EIF4GI gene portion

<400>  18
cccagacttc actccgtcct ttgccgactt cggccgacca gcccttagca accgtgggcc       60

cccaaggggt gggccaggtg gggagctgcc                                        90


